Trial NCT04352608, NCT04383574
Publication Zeng G, Lancet Infect Dis, 2021
Primary outcome on the report: 1) Any adverse reactions within 28 days after dose three 2) geometric mean titres (GMTs), geometric mean increases (GMIs), and seropositivity of neutralising antibodies to infectious SARS-CoV-2 28 days after the third dose

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.